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Abstract 
The creatine/phosphocreatine pathway plays a conserved and central role in energy metabolism. Compartmentaliza-
tion of specific creatine kinase enzymes permits buffering of local high energy phosphates in a thermodynamically 
favorable manner, enabling both rapid energy storage and energy transfer within the cell. Augmentation of this 
metabolic pathway by nutritional creatine supplementation has been shown to elicit beneficial effects in a number of 
diverse pathologies, particularly those that incur tissue ischemia, hypoxia or oxidative stress. In these settings, creatine 
and phosphocreatine prevent depletion of intracellular ATP and internal acidification, enhance post-ischemic recov-
ery of protein synthesis and promote free radical scavenging and stabilization of cellular membranes. The creatine 
kinase energy system is itself further regulated by hypoxic signaling, highlighting the existence of endogenous mech-
anisms in mammals that can enhance creatine metabolism during oxygen deprivation to promote tissue resolution 
and homeostasis. Here, we review recent insights into the creatine kinase pathway, and provide rationale for dietary 
creatine supplementation in human ischemic and inflammatory pathologies.
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Introduction
Creatine (Cr) plays a pivotal role in cellular energy home-
ostasis, particularly in tissues with highly dynamic energy 
demands such as the brain, striated muscle and the gut. 
Within the cell, creatine and its associated enzyme cre-
atine kinase (CK) facilitate the shuttling of high energy 
phosphates in the form of phosphocreatine (PCr) 
between sites of ATP generation, i.e. mitochondrial oxi-
dative phosphorylation and glycolysis, and compartmen-
talized ATP consumption. As such, the Cr/CK system 
defines an important and highly conserved phosphagen 
circuit, providing support for mitochondrial respiration 
and cellular energy turnover by mitigating temporal and 
spatial imbalances in ATP supply and demand [1].
Vertebrates express four distinct CK isozymes, and 
patterns of expression vary by tissue and by develop-
mental stage. Cytosolic muscle creatine kinase (CKM) 
is expressed primarily in sarcomeric skeletal and cardiac 
muscle cells, while the ubiquitous cytosolic brain isoform 
(CKB) is found in most non-muscle tissues. Two mito-
chondrial CK (mtCK) isoforms have also been charac-
terized, namely muscle-specific sarcomeric (smtCK) and 
ubiquitous mtCK, both of which localize to the mito-
chondrial intermembrane space [2]. Temporal and tissue-
specific CK expression is transcriptionally regulated by a 
number of factors, including myocyte-specific enhancer 
binding factor 2 (MEF-2) [3, 4], myogenic differentiation 
factor D (MyoD) [5], specificity protein 1 (Sp1) [6] and 
hypoxia-inducible factor (HIF) [7]. Moreover, substantial 
evidence from in vitro studies suggests that cytosolic and 
mitochondrial CK expression is modulated by estrogen 
receptor-mediated gene activation [8–10].
All CK isozymes catalyze the reversible transfer of 
γ-phosphate from ATP to the guanidino group of Cr to 
generate PCr and ADP, thus mediating efficient cytosolic 
storage of high-energy phosphates for rapid, focal ATP 
replenishment. The Cr/CK circuit is tightly linked to 
mitochondrial structure and energetics, as MitCK is cou-
pled to ATP export via the adenine nucleotide transporter 
(ANT), and to ATP synthesis and respiratory chain activ-
ity. This mitochondrial coupling reduces reactive oxygen 
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species (ROS) generation and inhibits mitochondrial per-
meability transition, an early event in apoptosis. The Cr/
CK reaction also modulates intracellular pH to protect 
cells from damage associated with internal acidification 
and ATP depletion [11, 12]. Furthermore, PCr can inter-
act with and protect cellular membranes [13], while Cr 
has been shown to scavenge free radicals and to harbor 
antioxidant properties [14, 15].
Dietary Cr supplementation increases the intracellular 
pool of Cr and PCr available for ATP generation, thereby 
supporting overall cellular energy homeostasis. As a 
nutritional supplement, Cr retains an excellent safety pro-
file even in aged individuals with chronic disorders, and 
has been widely used by athletes in recent decades as an 
ergogenic aid to improve muscle performance. Additional 
evidence from recent studies supports the use of Cr sup-
plementation as an adjuvant therapy in a diverse spec-
trum of disorders, whose central pathologies converge on 
a dysregulation of cellular bioenergetics. This review out-
lines our current understanding of the Cr/CK system in 
cellular energy homeostasis, and discusses recent compel-
ling evidence for the beneficial effects of Cr supplementa-
tion in inflammatory and ischemic disorders.
Disorders of creatine metabolism and transport
The daily Cr requirement for an average 70-kg adult 
male is approximately 2  g, up to half of which may be 
derived by intestinal absorption from dietary sources 
such as meat, fish and other animal products [16]. The 
remainder is synthesized de novo from arginine, gly-
cine and methionine by a two-step enzymatic reaction, 
utilizing arginine:glycine aminotransferase (AGAT) to 
generate guanidinoacetic acid (GAA) predominantly 
in the kidney, followed by hepatic methylation of GAA 
via guanidinoacetate methyltransferase (GAMT), using 
S-adenosylmethionine (SAM) as a methyl donor [17]. 
Cr biosynthesis accounts for  ~70  % of the total utiliza-
tion of labile methyl groups in the body, with SAM avail-
ability governed by levels of folate, vitamin B12, vitamin 
B2 and one-carbon precursors such as serine, histidine, 
tryptophan and choline [18, 19]. As such, deficiencies in 
folic acid and/or vitamin B12 are proposed to undermine 
GAA methylation and impact Cr biosynthesis [20]. Die-
tary and endogenous Cr enters systemic circulation and 
is actively transported into multiple tissue compartments 
by a transmembrane Na+ and Cl− -dependent creatine 
transporter (CrT), encoded by the SLC6A8 gene [21]. 
Approximately 1.5–2.0 % of the total Cr and PCr pool is 
degraded daily via simple non-enzymatic chemical dehy-
dration to creatinine, which is lost from cells by diffusion 
and targeted for urinary excretion [22].
Heritable defects in Cr biosynthesis (AGAT, GAMT) 
and Cr transport (SLC6A8) have been identified and are 
broadly characterized as Cr deficiency syndromes. Muta-
tions in AGAT and GAMT display an autosomal recessive 
pattern of inheritance, and deficiency in either of these 
enzymes manifests in developmental delay or regression, 
mental retardation, seizures and severe disturbance of 
expressive and cognitive speech [23]. Importantly, early 
detection and intervention with high dose Cr supplemen-
tation favorably impacts neurodevelopmental outcomes 
in affected individuals [24]. Polymorphisms in SLC6A8 
gene encoding the Cr transporter are a primary cause 
of X-linked mental retardation with a prevalence of 2 % 
in affected males, and have also been described in males 
with idiopathic mental retardation [25, 26]. Additional 
features of Cr transporter deficiency include delayed 
speech and language development with mild to moderate 
motor dysfunction, including extrapyramidal movement 
abnormalities. Interestingly, gastrointestinal problems 
such as neonatal feeding difficulties, vomiting and failure 
to thrive are also frequently associated, and among the 
earliest symptoms described [27]. These clinical obser-
vations suggest that Cr is imperative not only to cerebral 
function in the central nervous system, but also to gas-
trointestinal function and homeostasis.
Creatine, the intestinal barrier and inflammatory 
bowel disease
Cytosolic CKB is prominently expressed in smooth muscle 
and epithelial cells of the human intestine [28], and immu-
nolocalization studies indicate retention of the Na+Cl− 
dependent Cr transporter selectively to the enterocyte 
apical membrane [29]. The mode of intestinal Cr absorp-
tion in humans remains somewhat unclear, as transepi-
thelial transport of Cr would necessitate a basolateral 
membrane transporter that is not coupled to Na+Cl−. A 
second Cr transporter, the monocarboxylate transporter 
12 (MCT12), has recently been identified as a potential 
candidate for intestinal epithelial basolateral Cr transport 
[30]. Alternatively, intestinal Cr absorption may occur via 
paracellular movement by solvent drag transport, such that 
apical Cr uptake by epithelial cells is directed exclusively 
towards epithelial bioenergetics [31]. Recent findings have 
highlighted an important role for the Cr/CK shuttle in 
intestinal hypoxia and inflammation [7]. While this work 
focused largely on intestinal epithelial cells, additional 
studies indicate that gut homeostasis may also be modu-
lated by Cr/CK bioenergetics in the intestinal immune cell 
repertoire and Cr metabolism by gut microbiota.
Intestinal epithelial cells
Intestinal epithelia that line the gut mucosa constitute 
the primary cellular barrier against the external lumi-
nal environment. This highly dynamic barrier is intri-
cately regulated by myriad factors, including local oxygen 
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tension, to both accommodate nutrient and fluid trans-
port and exclude antigenic material [32]. Intestinal epi-
thelia are polarized, with apical surface features such as 
mucus secretion and intercellular junctions that are opti-
mized for luminal interaction and enteric microbe exclu-
sion. Within epithelia and other polarized cells, where 
mitochondria are located at a distance from subcellular 
regions of ATP consumption, differentially localized CK 
isozymes have been shown to facilitate a high-energy 
PCr/Cr circuit [11]. Early studies of CK in intestinal 
epithelia showed that while mitochondria and resident 
mtCK were excluded from brush borders by a dense 
cytoskeletal network, CKB localized to the brush bor-
der terminal web [33, 34]. Moreover, functional coupling 
between CKB and myosin II at the circumferential acto-
myosin ring was found to confer a spatial selective ener-
getic advantage for myosin ATPase activity, mediating 
the static tension and contractility of actin filaments. The 
cytoskeletal network that supports apical epithelial junc-
tions is among the most highly ordered arrays of actin fil-
aments in nature [35]. This actomyosin network mediates 
selective barrier function in health and disease [36] and 
is a primary target for molecular remodeling by diverse 
inflammatory stimuli [37]. Recent work showed that 
myosin II and cytosolic CKs are highly enriched at the 
apical adherens junction of polarized intestinal epithe-
lial cells, and pharmacological inhibition of CK markedly 
disrupts apical junction assembly and barrier integrity. 
Cytoskeletal and apical junction rearrangements that 
permit epithelial turnover and transepithelial transport 
are energy-dependent processes, and as such, structurally 
associated CK is poised to function as a conduit for rapid 
ATP generation in mucosal barrier dynamics (Fig. 1) [7].
Barrier dysregulation is a prominent determinant of 
susceptibility to inflammatory bowel disease (IBD). IBD 
encompasses a spectrum of chronic intestinal inflamma-
tory disorders with increasing global prevalence, with 
Crohn’s disease and ulcerative colitis comprising the pre-
dominant entities [38]. The mucosal barrier is subject to 
an austere oxygenation profile even under steady-state 
conditions, and intestinal inflammation incurs prodi-
gious metabolic shifts and further depletion of local oxy-
gen, culminating in hypoxic lesions. As such, hypoxia 
predominates normal intestinal metabolism and barrier 
regulation during both homeostasis and active inflam-
mation. Cellular programming by hypoxia-inducible 
factor (HIF) has been shown to tonally regulate epithe-
lial homeostasis, and to promote barrier function under 
inflammatory conditions associated with IBD [32, 39, 
40]. We recently examined the differential contribu-
tion of HIF-1α and HIF-2α to transcriptional changes in 
intestinal epithelia. For these purposes, we performed 
chromatin immunoprecipitation (ChIP) with HIF-1α 
and HIF-2α antibodies followed by hybridization to a 
promoter microarray. Highly enriched subsets of HIF-1α 
ChIP hits included multiple enzymes of the glycolytic 
pathway, autophagic targets and jumonji domain (JmjC) 
containing histone demethylases. In addition, this analy-
sis revealed prominent changes associated with metab-
olism, immunity and transcription. It is notable that 
promoter sequences for CKB and CKM genes emerged as 
high fidelity HIF-2 selective targets. Likewise, both mito-
chondrial isoforms of CK as well as the major creatine 
transporter SLC6A8 were significantly enriched in HIF-2 
ChIP. These studies also demonstrated that dietary sup-
plementation with 2 % Cr provided marked protection in 
two mouse models of experimental IBD.
Importantly, intestinal expression of mitochondrial 
and cytosolic CK enzymes was shown to be attenuated in 
clinical IBD biopsies. Reduced ATP levels have also been 
observed in inflamed tissue from patients with IBD [41], 
and non-inflamed biopsies obtained from Crohn’s disease 
patients are more sensitive to uncoupling of oxidative 
phosphorylation [42]. These observations are particu-
larly noteworthy, as chronic inflammation and the altered 
tissue metabolic profile associated with IBD is an estab-
lished major risk factor for colitis-associated colorectal 
cancer. The attenuated expression of CK enzymes in IBD 
tissue suggests that intestinal Cr metabolism and PCr/
CK energetics may be compromised in at least a subset of 
IBD patients, and several studies have identified reduced 
levels of CKB in colonic tumors [43, 44]. Moreover, over-
expression of dominant negative CKB mutants was found 
to promote an epithelial-to-mesenchymal transition 
(EMT) in colon cancer cells [45]. Overall, these findings 
indicate that impaired Cr/PCr shuttling may contrib-
ute to dysregulated mitochondrial energetics and the 
increased barrier permeability characteristic of inflamed 
mucosae. Most notably, this work highlights the potential 
for Cr supplementation in IBD to promote epithelial res-
titution and ameliorate mucosal inflammation.
Immune cells
Given the observation of dysregulated CK bioenergetics 
in IBD and the intimate integration of intestinal epithe-
lia with mucosal immune cells, an interesting correlate 
is the influence of Cr and CK on immune cell metabo-
lism and effector function in IBD and other inflamma-
tory diseases. The Cr/CK circuit in intestinal immune cell 
homeostasis remains largely uncharacterized, but several 
studies support a central role for Cr signaling in phago-
cytic function and T cell development. PCr and CK iso-
forms have been identified in mouse resident tissue and 
inflammation-elicited peritoneal macrophages, as well as 
in human monocyte-derived macrophage cultures [46]. 
CKB activity in macrophages has been shown to regulate 
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complement-induced F-actin assembly events in early 
phagocytosis, likely by providing focal ATP for cytoskel-
etal rearrangements [47, 48]. CKB has been implicated in 
metabolic regulation of T lineage cells, promoting acti-
vation, proliferation and cytokine secretion [49]. CK is 
also a component of platelets [46], and CKB binding to 
the thrombin receptor PAR-1 is thought to provide high 
energy phosphates for efficient receptor signal transduc-
tion during cytoskeletal reorganization [50]. Moreover, 
CK has recently been shown to dose-dependently inhibit 
ADP-induced platelet aggregation [51]. The relevance of 
this is underscored by clinical findings that IBD patients 
have an increased risk of thromboembolic complications 
and display abnormalities in thrombin generation, plate-
let activation and function [52, 53].
Gut microbiota
The mammalian gastrointestinal tract is host to a diverse 
microbial ecosystem that helps to shape host immunity 
and metabolism, as well as support epithelial barrier 
function. Several lines of evidence suggest that degrada-
tion of Cr and creatinine by gut microbiota may impact 
host physiology and pathology. In contrast to the non-
enzymatic conversion of PCr and Cr to creatinine that 
occurs in vertebrates, a growing number of microorgan-
isms have been shown to express specific enzymes such 
as creatinine deaminase and creatine amidinohydrolase 
that mediate creatinine and Cr breakdown. In several 
Bacillus, Clostridia and Escherichia strains, creatinine is 
degraded solely to 1-methylhydantoin and ammonia via 
creatinine deaminase, while in some Pseudomonas, Brev-
ibacterium and anaerobic Clostridia species, 1-methylhy-
dantoin can be degraded further to sarcosine and glycine 
[19]. Studies in uremic patients with highly elevated 
serum creatinine indicate that diffusion of creatinine into 
the gut lumen can induce microbial creatinine amidohy-
drolase, creatinine deaminase and Cr amidinohydrolase 



























Fig. 1 Cr/CK shuttle and the intestinal mucosal barrier. Cr is derived from dietary sources in the gastrointestinal tract, or by de novo synthesis 
synthesis primarily in the liver. The Na+ and Cl−-dependent creatine transporter (CrT) is expressed in the apical membrane of intestinal epithelial 
cells, facilitating Cr uptake from the gut lumen. Although intestinal Cr absorption in humans has not been well characterized, potential routes for Cr 
absorption into systemic circulation include paracellular movement by solvent drag transport, or via basolateral Cr transport by the monocarboxy-
late transporter 12 (MCT12). Gut microbiota express specific enzymes that can mediate Cr and creatinine breakdown. In hypoxic intestinal epithelial 
cells, cytosolic CK localizes to apical adherens junctions in complex with the actomyosin cytoskeletal network, providing a conduit for rapid ATP 
generation during the energy-dependent processes of epithelial junction assembly and barrier restitution
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recycling of Cr [54, 55]. Interestingly, gut microbial taxo-
nomic profiling in a mouse model of senescence recently 
revealed luminal Cr degradation as a prominent, over-
represented bacterial-encoded signature in older frail 
mice [56]. This finding is particularly intriguing in light 
of clinical studies that show Cr supplementation in the 
elderly promotes muscle strength and hypertrophy [57], 
and protects against age-related progressive muscle wast-
ing (sarcopenia) [58]. Whether the dysbiosis that is char-
acteristic of IBD can alter Cr metabolism in the gut has 
yet to be elucidated, but may define an important and 
previously overlooked axis of host-microbial crosstalk in 
intestinal inflammation.
Creatine and perinatal hypoxic ischemic injury
Oxygen deficit or asphyxia at birth is a significant peri-
natal complication that can result in neurodegeneration, 
cognitive and behavioral disturbances or neonatal mor-
tality [59]. Secondary to birth asphyxia, postnatal mani-
festation of hypoxic-ischemic encephalopathy (HIE) is 
associated with mild to severe multi-organ damage and 
development of chronic pathologies. Acute maternal 
intrauterine infection, premature delivery and multiple 
births are the most frequent natural risk factors leading 
to fetal or neonatal hypoxia [60]. Primary mechanisms 
of neurological damage include mitochondrial dysfunc-
tion, excitotoxic injury, impaired energy metabolism and 
oxidative stress. Experimental studies in animal mod-
els of birth hypoxia have identified a striking, markedly 
protective effect of maternal Cr supplementation during 
pregnancy on neonatal outcomes [61], and argue for the 
use of dietary Cr in pregnancy as a potential prophylactic 
therapy or adjunct to conventional treatments in at-risk 
obstetric populations.
Cr is thought to be actively transported across the pla-
centa from maternal circulation during pregnancy, with 
placental Cr transporter expression evident as early as 
13  weeks of gestation [62]. Expression of mitochondrial 
and cytosolic CK enzymes in the placenta is highly coor-
dinated and markedly increased in the third trimester, 
concomitant with increased metabolic activity of the 
placenta in late pregnancy [63]. It remains unclear when 
the human fetal reno-hepatic axis for endogenous Cr 
synthesis is established, although studies in the precocial 
spiny mouse indicate that this axis develops late in gesta-
tion [64]. Thus, the current paradigm implies an absolute 
requirement for fetal Cr transfer from placental Cr pools 
likely until late in fetal development, and suggests that 
infants born pre-term may have diminished capacity for 
Cr synthesis [61].
Initial studies of Cr-elicited protection in neona-
tal hypoxic/reperfusion injury focused on rodent fetal 
brain slices [65, 66] and neonatal rats [67]. These studies 
described sustained ATP turnover, reduced neuronal 
cell injury and enhanced post-ischemic recovery of pro-
tein synthesis with Cr pre-treatment. Cr has been shown 
to more readily access the fetal rodent brain than the 
mature adult brain, possibly due to non-carrier mediated 
diffusion [68] and/or higher levels of creatine transporter 
in endothelial cells of the choroid plexus [69]. Studies in 
the spiny mouse strain demonstrated that maternal die-
tary supplementation with 5 % Cr (approximately 1.36 g/
kg/day) from mid-pregnancy onwards promoted neonate 
survival and postnatal growth after intrapartum hypoxic 
insult [70]. In this model, the neuroprotective capacity of 
Cr in the hypoxic perinatal brain is attributed to reduced 
lipid peroxidation and apoptosis, likely through main-
tained mitochondrial function [71]. Importantly, sup-
plementation during pregnancy also enhanced Cr levels 
in embryonic peripheral organs known to be particularly 
susceptible to the global oxygen deprivation associated 
with perinatal asphyxia, supporting the systemic protec-
tive effect of Cr in fetal tissues. For instance, Cr loading in 
utero was found to markedly attenuate hypoxia-induced 
contractile dysfunction and fiber atrophy of the dia-
phragm muscle in the spiny mouse [72, 73]. Similarly, 
birth asphyxia led to disruption of neonatal renal archi-
tecture and increased levels of the early kidney injury 
marker NgaI, all of which were prevented by maternal 
dietary Cr supplementation [74]. In light of the recently 
described role for Cr and hypoxic signaling in the gut, a 
pertinent question is whether maternal Cr supplemen-
tation may also protect against necrotizing enterocolitis 
(NEC), a severe intestinal disorder prevalent in low birth 
weight, preterm infants [75]. Although the etiology of 
NEC is incompletely understood, contributing factors 
are thought to include immature intestinal motility and 
barrier function, inappropriate initial gut microbial colo-
nization and perinatal hypoxia/ischemia [76]. As such, 
NEC may define a novel candidate in a group of neonatal 
pathologies for which maternal Cr supplementation may 
prove beneficial.
Creatine in ischemic stroke
In addition to the fetal neuroprotective effects described 
above, experimental studies have demonstrated that pro-
phylactic Cr treatment is also widely neuroprotective in 
adult brain tissue against acute anoxic and ischemic cell 
damage that occurs in ischemic stroke and other cerebro-
vascular disorders. Early clinical studies in acute stroke 
patients revealed depletion of Cr and PCr in infarcted 
cerebral regions, suggesting that abrogated Cr/CK bio-
energetics may contribute to the pathogenic features of 
ischemic cerebral injury such as acidosis, ROS genera-
tion and cell death [77]. Studies employing adult rat hip-
pocampal slices demonstrated that Cr pre-incubation 
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mediates a dose-dependent increase in intracellular 
PCr, as well as delayed anoxic depolarization and pro-
tection against anoxia-induced impairment of protein 
synthesis and neuronal cell death [78, 79]. Dietary Cr 
pre-treatment in an experimental mouse stroke model 
was reported to mitigate ischemic neuronal cell death 
in part by inhibiting cytochrome c release and subse-
quent caspse-3 activation, possibly via primary buffer-
ing of ATP levels [80]. Mice pre-treated with oral Cr also 
showed faster recovery of cerebral blood flow during rep-
erfusion after transient focal cerebral ischemia, likely as 
a result of enhanced dilator responses to extra-luminal 
potassium and acidosis [81].
A recent clinical study has now extended these obser-
vations to human subjects [82]. Oral Cr supplementation 
(20 g/day for 7 days) in healthy young adults was found 
to augment neural Cr stores, increase corticomotor excit-
ability and prevent cognitive decline during acute oxygen 
deprivation. This study provides compelling in vivo evi-
dence that Cr may act as a neuroprotective supplement 
under conditions of compromised cellular oxygenation 
and bioenergetics. As outlined above, HIF is the pri-
mary ubiquitous mechanism for adaptive transcriptional 
responses to oxygen deprivation. Indeed, pharmacologi-
cal HIF stabilization has been shown to reduce brain tis-
sue injury and edema formation in ischemic stroke [83, 
84], while transgenic deletion of HIF-1α augments brain 
injury in models of neonatal hypoxia–ischemia [85, 86]. 
An important question, therefore, is how Cr supplemen-
tation may integrate with HIF-mediated transcription 
and enhanced neuronal CK expression in the setting of 
cerebral hypoxia or ischemia.
Creatine, CK and ischemic cardiovascular disease
The Cr/CK reaction is the major energy reserve of cardiac 
muscle cells, and myofibrillar ATP delivery is absolutely 
required to fuel normal contractile function. As such, a 
prevailing theory of heart failure posits that the failing 
heart is “energy-starved”. Indeed, impairment of the CK 
shuttle during heart failure has been recognized since 1939 
[39, 87] and reductions in Cr and CK activity have since 
been identified in most forms of clinical and experimental 
heart failure, regardless of pathogenesis [88, 89]. Cr loss in 
the failing heart is attributed in part to down-regulation of 
the cardiac creatine transporter [90], as a consequence of 
post-translational modification [91]. The energetic state of 
the heart is commonly reported as the PCr/ATP ratio, with 
a value of ~1.8 in the normal heart. Notably, ATP is main-
tained near normal levels until end-stage heart failure, due 
to the buffering capacity of PCr and the CK equilibrium 
constant strongly favoring ATP synthesis. Multiple stud-
ies have shown a reduced PCr/ATP ratio in patients with 
dilated cardiomyopathy [92, 93], and prior to overt cardiac 
dysfunction in hypertension [94], obesity [95] and type 2 
diabetes [96], suggesting a close association between car-
diac energetic status and function.
Myocardial ischemia is characterized by restriction of 
blood and oxygen supply to the myocardium. In its clas-
sic manifestation, cardiac ischemia results from occlu-
sion or narrowing of a coronary artery, inducing tissue 
hypoxia and rapid depletion of PCr and ATP levels [97]. 
Stress-induced reduction of the PCr/ATP ratio in female 
patients with chest pain consistent with myocardial 
ischemia was found to be a strong predictor of future car-
diovascular events [98]. In  vivo studies in patients with 
prior myocardial infarction using phosphorous magnetic 
resonance spectroscopy ([31] P-MRS) showed that CK 
flux is reduced in ischemic myocardium, commensurate 
with the extent of infarct transmurality [99].
Evidence exists to indicate that augmentation of CK 
and its reactants may prove beneficial in ischemic car-
diac disease [100]. Hearts from Cr-deficient GAMT 
knockout mice displayed reduced inotropic reserve and 
impaired functional recovery following an ischemic epi-
sode [101]. Interestingly, PCr treatment reduced necrotic 
tissue injury and improved contractile function in animal 
models of coronary artery ligation [102] and ischemia–
reperfusion injury [103]. More recently, PCr adminis-
tration was found to prevent ventricular dysfunction in 
a rodent model of transient coronary occlusion [104]. In 
the clinical setting, significant myocardial protection was 
reported in patients undergoing coronary artery bypass 
surgery upon administration of exogenous PCr before, 
during and post-surgery [105]. Moreover, patients treated 
with intravenous PCr had reduced incidence of both ven-
tricular fibrillation and ventricular tachycardia post myo-
cardial infarction [106]. PCr is not a known substrate of 
the creatine transporter [107], and there is limited infor-
mation on actual uptake of PCr by the human heart. 
However, PCr uptake has been demonstrated in ex vivo 
perfused rodent hearts [108] and isolated rat mitochon-
dria and liposomes [109]. Furthermore, PCr is proposed 
to protect the cardiomyocyte sarcolemma [13, 105] and 
to inhibit platelet aggregation [51, 110], thus likely exert-
ing a beneficial effect in coronary thrombosis.
Proof-of-principle experimental studies utilizing knockin 
mice have also demonstrated that transgenic overexpres-
sion of the cardiac creatine transporter or the muscle CK 
isoform CKM can elicit marked protection against stress-
induced heart injury. Creatine transporter overexpres-
sion was reported to protect against ischemia–reperfusion 
injury, with improved cardiac energetics and delayed mito-
chondrial permeability transition pore opening in response 
to oxidative stress. Importantly, the extent of myocardial 
damage was found to negatively correlate with tissue Cr 
levels [111]. Transgenic CKM overexpressing mice were 
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found to maintain CK flux at higher levels in a heart failure 
model of pressure overload, associated with higher ejection 
fraction and improved survival [112].
Interestingly, several studies have implicated the HIF 
pathway in ischemic preconditioning-mediated cardiac 
protection from ischemic–reperfusion injury [113–115] 
and prolonged HIF stabilization improves cardiac func-
tion in myocardial ischemia [116]. Given the functional 
regulation of CK metabolism by HIF in the gut, an open 
question is whether HIF-mediated protection from 
ischemic damage by ischemic preconditioning may also 
extend to enhanced CK expression and Cr metabolism 
in the heart. In sum, while future studies are needed to 
determine the factors that impair CK energy metabolism 
and creatine transporter activity in failing or ischemic 
hearts, current work supports the Cr/PCr pathway as a 
promising therapeutic target for preventing and treating 
ischemic cardiovascular disease.
Conclusions
Although the use of creatine in patients during preg-
nancy and IBD has yet to be fully evaluated, its profile as 
a safe nutritional supplement in diverse patient popula-
tions is well documented. Creatine has been shown not 
only to increase muscle mass and prevent age- and dis-
ease-related muscle atrophy, but also to enhance overall 
tissue bioenergetics in a range of pathologies. Clinical 
evidence strongly supports the profoundly neuropro-
tective properties of creatine and the beneficial effects 
of phosphocreatine in cardiovascular stress. Although 
further work is needed to establish causality, both pre-
clinical and clinical studies provide correlative evidence 
that energetic changes and dysregulation of the Cr/CK 
pathway are closely linked with the etiology of hypoxic 
and inflammatory disorders. Altered Cr metabolism by 
the gut microbiota may define an important influence on 
the human host creatine pathway, particularly in the con-
text of dysbiosis associated with aging, obesity and IBD. 
Overall, dietary creatine is a promising candidate as an 
independent prophylactic treatment or as an adjunct to 
conventional therapies for ischemic disease.
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